Beecham Group plc Credit Rating

Results 1 - 50 Of 330

Page Of 7 Next

Filter By:

Date	Document Type	Title	Source
16 Jan 2020	Compilation	Healthcare Quarterly: January 2020	Moody's Investors Service
16 Jan 2020	Sector Comment	Branded Pharmaceuticals - US: Drug pricing reform and M&A will drive 2020 credit quality	Moody's Investors Service
11 Dec 2019	Outlook	Healthcare – Global: 2020 outlook mostly stable as efforts by payers to reduce costs temper rising utilization of healthcare products and services (Slides)	Moody's Investors Service
09 Dec 2019	Sector In-Depth	Nonfinancial companies – Japan: New accounting standard for operating leases has little impact on credit metrics	Moody's Investors Service
25 Nov 2019	Sector In-Depth	Pharmaceuticals - Global: Rybelsus approval shakes up diabetes with mixed credit effects for drugmakers	Moody's Investors Service
24 Oct 2019	Compilation	Healthcare Quarterly: October	Moody's Investors Service
24 Oct 2019	Sector Comment	Branded Pharmaceuticals - US: Possibility of drug pricing reform increasing as public scrutiny remains high	Moody's Investors Service
02 Oct 2019	Sector Comment	Pharmaceuticals, drug distributors and drug retailers - US: Developments in opioid litigation suggest global settlements are nearing	Moody's Investors Service
02 Oct 2019	Outlook	Pharmaceuticals - Global: Outlook update: Product uptake supports growth, even as social risks increase	Moody's Investors Service
24 Sep 2019	Sector In-Depth	Pharmaceuticals - Global: China's pharma market offers good growth prospects for foreign firms through 2023	Moody's Investors Service
07 Aug 2019	Sector In-Depth	Pharmaceuticals - US: Newest proposals to reduce US drug prices raise industry's social and financial risks	Moody's Investors Service
29 Jul 2019	Sector Comment	Branded Pharmaceuticals - US: Artificial intelligence, CRISPRs and other technologies will help drug development	Moody's Investors Service
29 Jul 2019	Compilation	Healthcare Quarterly: July 2019	Moody's Investors Service
12 Jul 2019	Sector Comment	Pharmaceuticals - Global: Rising competition in HIV will steadily pressure market leader Gilead Sciences	Moody's Investors Service
13 Jun 2019	Sector Comment	Pharmaceuticals - Global: Investment-grade drug companies have good M&A capacity as acquisitions continue	Moody's Investors Service
10 Jun 2019	Sector In-Depth	Non-financial corporates – US: Cash pile declines 15.2% as capex, dividends, buybacks and acquisitions hit record highs	Moody's Investors Service
03 Jun 2019	Sector In-Depth	Pharmaceuticals and distributors - US: Opioid litigation advances, providing early clues into some liability exposures	Moody's Investors Service
24 Apr 2019	Sector Comment	Generic Pharmaceuticals – US: Strong demand for lower-cost drugs would insulate generic drugmakers in a downturn	Moody's Investors Service
24 Apr 2019	Sector Comment	Branded Pharmaceuticals - US: Limited exposure to an economic slowdown except for cash-pay businesses	Moody's Investors Service
24 Apr 2019	Compilation	Healthcare Quarterly: April 2019	Moody's Investors Service
17 Apr 2019	Outlook	Pharmaceuticals - Global: Product uptake drives stable outlook amid rising price pressure and regulatory threats	Moody's Investors Service
17 Apr 2019	Sector In-Depth	Global Pharmaceuticals Snapshot: Patent cliff slightly eases while pipeline quality holds steady	Moody's Investors Service
10 Apr 2019	Compilation	Inside Japan: April 2019	Moody's Investors Service
28 Feb 2019	Sector Comment	Pharmaceuticals - Europe: Capacity to absorb M&A without risking credit quality deterioration varies	Moody's Investors Service
18 Feb 2019	Sector Comment	Pharmaceuticals - Europe: Earnings growth set to accelerate, but move to specialty care raises business risks	Moody's Investors Service
07 Feb 2019	Sector In-Depth	Pharmaceuticals - US: Increasing efforts to curb drug prices raise financial risk for pharmaceutical companies	Moody's Investors Service
18 Jan 2019	Sector Comment	Pharmaceuticals - General & Specialty: Political risks, oncology market and acquisitions will shape industry in 2019	Moody's Investors Service
18 Jan 2019	Sector Comment	Generic Pharmaceuticals - US : Developments to watch: 2019	Moody's Investors Service
18 Jan 2019	Compilation	Healthcare Quarterly: January 2019	Moody's Investors Service
06 Dec 2018	Outlook	Healthcare – Global: 2019 outlook reflects both rising spending and rising political risk (Slides)	Moody's Investors Service
27 Nov 2018	Outlook	Non-financial corporates - Japan : 2019 Outlook (Slides)	Moody's Investors Service
15 Nov 2018	Sector Comment	Pharmaceuticals - US: Though down from their peak, cash levels are rising, portending more M&A ahead	Moody's Investors Service
31 Oct 2018	Sector Comment	Pharmaceuticals - Global: Plan to lower Medicare Part B payments would pressure US drug prices, if adopted	Moody's Investors Service
22 Oct 2018	Sector Comment	Pharmaceuticals - US: Political risks rise as regulators contemplate ideas outlined in drug pricing blueprint	Moody's Investors Service
22 Oct 2018	Compilation	Healthcare Quarterly: October 2018	Moody's Investors Service
18 Oct 2018	Sector In-Depth	Non-financial companies - Japan: Cross-border financing rises as companies look abroad for growth	Moody's Investors Service
10 Oct 2018	Compilation	Inside Japan: October 2018	Moody's Investors Service
10 Oct 2018	Sector In-Depth	Non-financial companies - Japan: Cash level remains high, but growth will slow as spending increases	Moody's Investors Service
08 Oct 2018	Sector Comment	Pharmaceuticals - Global : US approval of Hemlibra is credit positive for Roche, but will pressure rival drugs	Moody's Investors Service
04 Oct 2018	Sector In-Depth	Pharmaceuticals - Global: Biosimilars: European sales accelerate, while regulatory changes will help US market	Moody's Investors Service
20 Sep 2018	Outlook	Pharmaceuticals - Global: Modest pick-up in growth on strong product launches, but regulatory risk escalates	Moody's Investors Service
02 Aug 2018	Sector Comment	Pharmaceuticals - Global: US drugs face heightened pricing pressure and regulatory risk	Moody's Investors Service
26 Jul 2018	Sector In-Depth	Pharmaceuticals - Global: European Investor Roundtables - Q&A Highlights	Moody's Investors Service
12 Jul 2018	Sector Comment	Generic Pharmaceuticals - US: Midyear update: Developments to watch in 2018	Moody's Investors Service
12 Jul 2018	Sector Comment	Pharmaceuticals - General & Specialty - US: Midyear update: M&A off to brisk pace globally, with more to come from US	Moody's Investors Service
12 Jul 2018	Compilation	Healthcare Quarterly: July 2018	Moody's Investors Service
11 Jul 2018	Sector In-Depth	Pharmaceuticals - Europe: Strong pipelines suggest acceleration of earnings growth into 2019	Moody's Investors Service
15 May 2018	Sector Comment	Pharmaceuticals - Global: Proposals to lower US drug prices would be credit negative, if adopted	Moody's Investors Service
08 May 2018	Sector Comment	Consumer, Tobacco and Pharmaceuticals: US: Companies invest in marijuana to learn more about its challenges and opportunities	Moody's Investors Service
20 Apr 2018	Sector In-Depth	Global Pharmaceuticals Snapshot: Pipelines still good while patent expirations will remain modest over next three years	Moody's Investors Service

Results 1 - 50 Of 330

Page Of 7 Next

Registered User

Not Registered Yet?